JP2011525895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525895A5 JP2011525895A5 JP2011515386A JP2011515386A JP2011525895A5 JP 2011525895 A5 JP2011525895 A5 JP 2011525895A5 JP 2011515386 A JP2011515386 A JP 2011515386A JP 2011515386 A JP2011515386 A JP 2011515386A JP 2011525895 A5 JP2011525895 A5 JP 2011525895A5
- Authority
- JP
- Japan
- Prior art keywords
- derivative according
- amylin
- albumin binding
- group
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000009027 Albumins Human genes 0.000 claims 10
- 108010088751 Albumins Proteins 0.000 claims 10
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 5
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 101100284231 Caenorhabditis elegans his-24 gene Proteins 0.000 claims 1
- 101100338242 Drosophila virilis His1.1 gene Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08158995.4 | 2008-06-25 | ||
| EP08158995 | 2008-06-25 | ||
| PCT/EP2009/057972 WO2009156473A1 (en) | 2008-06-25 | 2009-06-25 | Derivatised hybrid peptides of amylin and salmon calcitonin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011525895A JP2011525895A (ja) | 2011-09-29 |
| JP2011525895A5 true JP2011525895A5 (enExample) | 2012-06-28 |
Family
ID=41278557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515386A Withdrawn JP2011525895A (ja) | 2008-06-25 | 2009-06-25 | アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110152183A1 (enExample) |
| EP (1) | EP2293811A1 (enExample) |
| JP (1) | JP2011525895A (enExample) |
| CN (1) | CN102076353A (enExample) |
| WO (1) | WO2009156473A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2493919A1 (en) * | 2009-10-30 | 2012-09-05 | Novo Nordisk A/S | Derivatives of cgrp |
| JP6121992B2 (ja) | 2011-06-10 | 2017-04-26 | ノヴォ ノルディスク アー／エス | ポリペプチド |
| WO2016034604A1 (en) * | 2014-09-04 | 2016-03-10 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| CN104888198A (zh) * | 2015-04-21 | 2015-09-09 | 徐志强 | 降钙素在制造延缓脑老化药物的新用途 |
| RU2699800C2 (ru) * | 2017-11-01 | 2019-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ уменьшения гипертензивного эффекта хлорида кобальта кальцитонином |
| GB202217575D0 (en) * | 2022-11-24 | 2023-01-11 | Imperial College Innovations Ltd | Novel compounds |
| WO2024189611A1 (en) * | 2023-03-13 | 2024-09-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Stabilized analogues of calcitonin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5321008A (en) * | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
| ATE471340T1 (de) * | 2004-02-11 | 2010-07-15 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
| WO2007055728A1 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| CN102343084A (zh) * | 2005-03-31 | 2012-02-08 | 安米林药品公司 | 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂 |
| JP5252435B2 (ja) * | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| AU2006341375B2 (en) * | 2006-03-31 | 2013-03-21 | Amylin Pharmaceuticals, Llc | Amylin and amylin agonists for treating psychiatric diseases and disorders |
-
2009
- 2009-06-25 CN CN2009801256277A patent/CN102076353A/zh active Pending
- 2009-06-25 JP JP2011515386A patent/JP2011525895A/ja not_active Withdrawn
- 2009-06-25 US US13/000,225 patent/US20110152183A1/en not_active Abandoned
- 2009-06-25 EP EP09769321A patent/EP2293811A1/en not_active Withdrawn
- 2009-06-25 WO PCT/EP2009/057972 patent/WO2009156473A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525895A5 (enExample) | ||
| KR102497726B1 (ko) | 인슐린 저항성에 대한 개선된 펩티드 제약 | |
| JP2012506402A5 (enExample) | ||
| JP7484018B2 (ja) | Ｇｌｐ－１プロドラッグおよびその使用 | |
| JP5209463B2 (ja) | アシル化ｇｌｐ−１化合物 | |
| CN101400698A (zh) | 胰岛淀粉样多肽衍生物 | |
| JP7642830B2 (ja) | 代謝及び肝臓障害の処置のための組成物及び方法 | |
| JP7834640B2 (ja) | ペプチドコンジュゲートおよび使用方法 | |
| JP2012529463A (ja) | ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ | |
| KR20060109940A (ko) | 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체 | |
| CN101128214A (zh) | 长效glp-1化合物 | |
| AU2009248041A1 (en) | Long-acting Y2 and/or Y4 receptor agonists | |
| WO2011134284A1 (zh) | 胰高血糖素样肽-1类似物及其应用 | |
| JP2012504619A5 (enExample) | ||
| JP2024522196A (ja) | 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法 | |
| AU2019259790A1 (en) | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | |
| CA2754140C (en) | Oral delivery of hydrophilic drugs to the brain | |
| KR101609302B1 (ko) | 새로운 글루카곤 유사 펩타이드 유사체, 조성물, 및 사용 방법 | |
| KR20190019030A (ko) | 아실화 옥신토모듈린 펩타이드 유사체 | |
| CN102076353A (zh) | 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽 | |
| CN116490212A (zh) | Glp-1前药及其用途 | |
| CA3177863A1 (en) | Long-acting glp-1 and glucagon receptor dual agonist | |
| JPH05506657A (ja) | マクロファージ活性化用組成物 | |
| EP1963343A1 (en) | Polypeptide protracting tags | |
| JP2016526533A (ja) | アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体 |